Research records indexed for Semaglutide
This page carries 12 of the 5,682 records that the literature query returned for Semaglutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 5,670 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Semaglutide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis pmid:40305708 | 2025 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Liver; Liver Cirrhosis; Biopsy; Injections, Subcutaneous; Drug Administration Schedule. |
| Tirzepatide as Compared with Semaglutide for the Treatment of Obesity pmid:40353578 | 2025 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Obesity; Body Weight; Weight Loss; Anti-Obesity Agents; Injections, Subcutaneous. |
| Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes pmid:40162642 | 2025 | Equivalence Trial, Multicenter Study | human trial | Not stated | Indexed as equivalence trial, multicenter study. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Administration, Oral; Follow-Up Studies; Atherosclerosis. |
| Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial pmid:39937469 | 2025 | Clinical Trial, Phase II, research-article | human trial | Not stated | Indexed as clinical trial, phase ii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Alcoholism; Drug Administration Schedule; Alcohol Drinking; Glucagon-Like Peptide 1; Glucagon-Like Peptides. |
| Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes pmid:38785209 | 2024 | Multicenter Study, Randomized Controlled Trial | human trial | Not stated | Indexed as multicenter study, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetic Nephropathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Glomerular Filtration Rate. |
| Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes pmid:38587233 | 2024 | Randomized Controlled Trial | human trial | Not stated | Indexed as randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Glucagon-Like Peptides; Heart Failure. |
| Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials pmid:38599221 | 2024 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Obesity; Stroke Volume; Glucagon-Like Peptides; Heart Failure; Semaglutide. |
| Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial pmid:38740993 | 2024 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Cardiovascular Diseases; Obesity; Weight Loss; Body Mass Index; Glucagon-Like Peptides. |
| Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis pmid:39476339 | 2024 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Arthralgia; Osteoarthritis, Knee; Obesity; Weight Loss; Pain Measurement. |
| Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity pmid:38976257 | 2024 | Comparative Study, Research Support, Non-U.S. Gov't | other | Not stated | Indexed as comparative study, research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Retrospective Studies; Cohort Studies. |
| Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide pmid:38958939 | 2024 | research-article | other | Not stated | Indexed as research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Optic Neuropathy, Ischemic; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Incidence; Risk Factors. |
| Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials pmid:39222642 | 2024 | Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as research support, n.i.h., intramural, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Hospitalization; Glucagon-Like Peptides. |
Where this page sits
Compound page: Semaglutide. Class: Incretin receptor agonists.
Retrieved 2026-10-10.
Sources
- PubChem Compound Summary for CID 56843331, Semaglutide. PubChem, National Library of Medicine (2026). pubchem:56843331
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213051. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:semaglutide
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med (2016). pmid:27633186
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med (2021). pmid:33567185
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med (2023). pmid:37952131
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med (2021). pmid:33185364
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med (2024). pmid:38785209
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.